Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 49 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 10265387

    Compositions and methods for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  2. US 10265368

    Date pit composition for the treatment of animals

    UNITED ARAB EMIRATES UNIVERSITY · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  3. US 10265282

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  4. US 10258631

    Formulations of testosterone and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  5. US 10261095

    Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment

    Julius-Maximilians-Universitat Wurzburg · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  6. US 10259780

    Treatment of cataplexy

    Jazz Pharmaceuticals International III Limited · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  7. US 10253294

    Galactose oxidase treatment of dendritic cells to improve their immunogenicity

    Julius-Maximilians-Universitat Wurzburg · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted

  8. US 10245255

    Compositions and methods for the treatment of obesity and related disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  9. US 10238659

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  10. US 10238606

    Pharmaceutical compositions for the treatment of Helicobacter pylori

    RedHill Biopharma Ltd. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  11. US 10238618

    Compositions and methods for diagnosis and treatment of anemia

    United States of America as represented by the Secretary of the Air Force · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  12. US 10239911

    Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  13. US 10238652

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  14. US 10231932

    Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  15. US 10232044

    Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

    The Regents of the University of California · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  16. US 10233222

    Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  17. US 10231983

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  18. US 2019076525

    THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS GMBH [DE] · Granted Mar 14, 2019 · Expires Mar 9, 2039

    granted

  19. US 10227312

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  20. US 10226472

    Methods for the treatment of breast cancer

    Syndax Pharmaceuticals, Inc. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  21. US 10227323

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  22. US 10226420

    Methods of eye treatment using therapeutic compositions containing dipyridamole

    O.D. Ocular Discovery Ltd. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  23. US 10221226

    LEDGF peptides and formulations thereof for treatment of degenerative disorders

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  24. US 10220029

    Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.